Abstract:Agonists of GPR40 (FFA1) have been proposed as a means to treat type 2 diabetes. Through lead optimization of a high throughput screening hit, we have identified a novel GPR40 agonist called AMG 837. The objective of these studies was to understand the preclinical pharmacological properties of AMG 837. The activity of AMG 837 on GPR40 was characterized through GTP gamma S binding, inositol phosphate accumulation and Ca2+ flux assays. Activity of AMG 837 on insulin release was assessed on isolated primary mouse islets. To determine the anti-diabetic activity of AMG 837 in vivo, we tested AMG 837 using a glucose tolerance test in normal Sprague-Dawley rats and obese Zucker fatty rats. AMG 837 was a potent partial agonist in the calcium flux assay on the GPR40 receptor and potentiated glucose stimulated insulin secretion in vitro and in vivo. Acute administration of AMG 837 lowered glucose excursions and increased glucose stimulated insulin secretion during glucose tolerance tests in both normal and Zucker fatty rats. The improvement in glucose excursions persisted following daily dosing of AMG 837 for 21-days in Zucker fatty rats. Preclinical studies demonstrated that AMG 837 was a potent GPR40 partial agonist which lowered post-prandial glucose levels. These studies support the potential utility of AMG 837 for the treatment of type 2 diabetes.

Discovery of the Imidazole-Derived Gpr40 Agonist Am-3189

Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.

Optimization of GPR40 Agonists for Type 2 Diabetes.

Amg 837: A Novel Gpr40/Ffa1 Agonist That Enhances Insulin Secretion And Lowers Glucose Levels In Rodents

AMG 837: a potent, orally bioavailable GPR40 agonist.

Discovery And Optimization Of Potent Gpr40 Full Agonists Containing Tricyclic Spirocycles

Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist That Displays Efficacy in Nonhuman Primates.

Discovery of Novel Potent GPR40 Agonists Containing Imidazo[1,2-A]pyridine Core As Antidiabetic Agents.

Discovery of Pyrrolidine-Containing Gpr40 Agonists: Stereochemistry Effects A Change in Binding Mode

Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists.

Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole.

Discovery of 5-Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1h)-one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119.

Design, Synthesis, and Biological Evaluations of Phenylpropiolic Acid Derivatives As Novel GPR40 Agonists

Discovery of (S)-3-(4-(benzyloxy)phenyl)-2-(2-phenoxyacetamido)propanoic Acid Derivatives As a New Class of GPR34 Antagonists.

Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists.

Design and Biological Evaluation of Tetrahydropyridine Derivatives As Novel Human GPR119 Agonists

Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold

Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor

Discovery of 3-((4-Benzylpyridin-2-yl)amino)benzamides as Potent GPR52 G Protein-Biased Agonists

Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.